Targeting the NLRP3 inflammasome in psoriasis.

Abstract

The NLRP3 inflammasome, a complex consisting of the nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain-containing protein 3, has emerged as a critical mediator of pathological inflammation and a significant therapeutic target for various inflammatory diseases. Psoriasis, a chronic inflammatory skin condition without a definitive cure, has shown promising results in animal models through the inhibition of the NLRP3 inflammasome. This review aims to explore the development of the NLRP3 inflammasome in psoriasis and the molecular mechanisms responsible for its inhibition by natural products and small molecules currently being developed for psoriasis treatment. Furthermore, we are examining clinical trials using agents that block the NLRP3 pathway for the treatment of psoriasis. This study is timely to provide a new perspective on managing psoriasis.

• Authors: Xiuhui Chen, Guoliang Deng, Kaifeng Chen, Yanhong Chen, Weijun Ye, Ping Sun
• Journal: International journal of dermatology (Int J Dermatol) (Feb 12 2024) ISSN: 1365-4632 [Electronic] England
• PMID: 38345734 (Publication Type: Journal Article, Review)
• Copyright: © 2024 the International Society of Dermatology.